FR2854073B1 - Composition pharmaceutique solide comprenant un agoniste du recepteur s1p et un alcool de sucre - Google Patents

Composition pharmaceutique solide comprenant un agoniste du recepteur s1p et un alcool de sucre

Info

Publication number: FR2854073B1
Authority: FR; France
Prior art keywords: pharmaceutical composition; receptor agonist; sugar alcohol; solid pharmaceutical; oral administration
Prior art date: 2003-04-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

FR0450692A

Other languages

English (en)

Other versions

FR2854073A1 (fr

Inventor

Tomoyuki Oomura

Madhusudhan Pudipeddi

Colleen Ruegger

Alan Edward Royce

Masaki Sasaki

Tokuhiro Tamura

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Tanabe Pharma Corp

Original Assignee

Novartis AG

Mitsubishi Pharma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-08

Filing date

2004-04-06

Publication date

2008-03-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2854073(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-04-06 Application filed by Novartis AG, Mitsubishi Pharma Corp filed Critical Novartis AG

2004-10-29 Publication of FR2854073A1 publication Critical patent/FR2854073A1/fr

2008-03-14 Application granted granted Critical

2008-03-14 Publication of FR2854073B1 publication Critical patent/FR2854073B1/fr

2024-04-06 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Emergency Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Oil, Petroleum & Natural Gas (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Biochemistry (AREA)
Heart & Thoracic Surgery (AREA)
Transplantation (AREA)
Virology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Surgery (AREA)
Hospice & Palliative Care (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

FR0450692A 2003-04-08 2004-04-06 Composition pharmaceutique solide comprenant un agoniste du recepteur s1p et un alcool de sucre Expired - Lifetime FR2854073B1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US46121503P	2003-04-08	2003-04-08

Publications (2)

Publication Number	Publication Date
FR2854073A1 FR2854073A1 (fr)	2004-10-29
FR2854073B1 true FR2854073B1 (fr)	2008-03-14

Family

ID=32326722

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
FR0450692A Expired - Lifetime FR2854073B1 (fr)	2003-04-08	2004-04-06	Composition pharmaceutique solide comprenant un agoniste du recepteur s1p et un alcool de sucre
FR11C0036C Active FR11C0036I2 (fr)	2003-04-08	2011-09-08	Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
FR11C0036C Active FR11C0036I2 (fr)	2003-04-08	2011-09-08	Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre

Country Status (41)

Country	Link
US (11)	US20060275357A1 (fr)
EP (5)	EP2319502A1 (fr)
JP (3)	JP5495467B2 (fr)
KR (3)	KR101367574B1 (fr)
CN (2)	CN1767819B (fr)
AR (3)	AR043987A1 (fr)
AT (3)	AT501681B1 (fr)
AU (1)	AU2004228929B2 (fr)
BE (2)	BE1015972A5 (fr)
BR (1)	BRPI0409250B8 (fr)
CA (2)	CA2707750A1 (fr)
CL (2)	CL2004000745A1 (fr)
CY (3)	CY1110260T1 (fr)
DE (4)	DE102004016947A1 (fr)
DK (2)	DK1613288T3 (fr)
EC (1)	ECSP056090A (fr)
ES (3)	ES2228282B1 (fr)
FR (2)	FR2854073B1 (fr)
GB (1)	GB2400318B (fr)
GR (1)	GR1005052B (fr)
HR (3)	HRP20050886B1 (fr)
HU (2)	HUE028247T2 (fr)
IL (3)	IL170888A (fr)
IS (2)	IS2682B (fr)
IT (1)	ITMI20040682A1 (fr)
LU (1)	LU91867I2 (fr)
MA (1)	MA27729A1 (fr)
MX (1)	MXPA05010860A (fr)
MY (1)	MY141249A (fr)
NO (4)	NO329332B1 (fr)
NZ (3)	NZ586280A (fr)
PE (5)	PE20050396A1 (fr)
PL (2)	PL1613288T3 (fr)
PT (1)	PT1613288E (fr)
RU (5)	RU2358716C2 (fr)
SG (1)	SG175449A1 (fr)
SI (2)	SI1613288T1 (fr)
TN (1)	TNSN05256A1 (fr)
TW (1)	TWI332847B (fr)
WO (1)	WO2004089341A1 (fr)
ZA (1)	ZA200507394B (fr)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5214966B2 (ja) *	2004-07-30	2013-06-19	ノバルティスアーゲー	２−アミノ−１，３−プロパンジオール化合物およびその類似体の製剤
CN1891212B (zh) *	2005-07-07	2010-10-13	马启明	一种口服制剂及其制备方法
ES2357426T3 (es) *	2005-09-09	2011-04-26	Novartis Ag	Tratamiento de enfermedades autoinmunes.
PL1948678T3 (pl)	2005-11-09	2013-09-30	Onyx Therapeutics Inc	Związki do hamowania enzymów
TWI389683B (zh) *	2006-02-06	2013-03-21	Kyorin Seiyaku Kk	A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
CA2657213C (fr)	2006-06-19	2017-01-03	Proteolix, Inc.	Peptides epoxycetones pour l'inhibition de proteasomes
GB0612721D0 (en)	2006-06-27	2006-08-09	Novartis Ag	Organic compounds
EP1923054A1 (fr) *	2006-09-26	2008-05-21	Novartis AG	Composition pharmaceutique à désintégration rapide comprenant un agoniste ou modulateur de S1P
EP1923058A1 (fr) *	2006-09-26	2008-05-21	Novartis AG	Composition pharmaceutique enrobée comprenant un agoniste ou un modulateur de S1P
CN105012266A (zh) *	2006-09-26	2015-11-04	诺华股份有限公司	包含s1p调节剂的药物组合物
AU2011235934A1 (en) *	2006-09-26	2011-11-03	Novartis Ag	Pharmaceutical compositions comprising an S1P modulator
EP1905434A1 (fr) *	2006-09-26	2008-04-02	Novartis AG	Compositions organiques comprenant d'un agoniste de S1P recepteur et leur utilisation therapeutique
EP1923055A1 (fr) *	2006-09-26	2008-05-21	Novartis AG	Composition pharmaceutique lyophilisée comprenant un agoniste ou modulateur de S1P
WO2008124210A1 (fr) *	2007-02-14	2008-10-16	Emory University	Procédés et compositions destinés à traiter ou prévenir une infection en utilisant des agents de séquestration des leucocytes
PL2140867T5 (pl) *	2007-03-29	2023-10-30	Daiichi Sankyo Company, Limited	Kompozycja farmaceutyczna
CL2008002966A1 (es)	2007-10-04	2010-06-25	Onyx Therapeutics Inc	Compuesto tetrapeptido ceto-epoxido cristalino; sal citrato cristalina del compuesto; metodos de preparacion; compuesto intermediario cristalino; metodo de preparacion; y uso para tratar cancer, enfermedad autoinmune, afeccion relacionada con trasplante, enfermedad neurodegenerativa, afeccion asociada con fibrosis, entre otros.
NZ600355A (en) *	2007-10-12	2013-02-22	Novartis Ag	Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
AU2012216630B2 (en) *	2007-10-12	2015-01-22	Novartis Ag	Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
JP5534645B2 (ja) *	2008-01-11	2014-07-02	日医工株式会社	無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
WO2009099174A1 (fr)	2008-02-07	2009-08-13	Kyorin Pharmaceutical Co., Ltd.	Agent thérapeutique ou agent préventif pour maladie inflammatoire des intestins contenant un dérivé d'alcool aminé comme composant actif
KR101718639B1 (ko)	2008-03-17	2017-03-21	액테리온 파마슈티칼 리미티드	선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생
BRPI0914164B1 (pt) *	2008-06-20	2019-04-30	Merck Patent Gmbh	Comistura para produção de comprimidos de desintegração rápida em um processo de formação de comprimido direto, seus usos, e formulações de comprimido
KR20110020928A (ko)	2008-06-20	2011-03-03	노파르티스 아게	다발성 경화증을 치료하기 위한 소아용 조성물
SI2334202T1 (sl) *	2008-09-04	2012-04-30	Cargill Inc	Tabletiranje eritritola
EP2349313A4 (fr)	2008-10-21	2012-08-29	Onyx Therapeutics Inc	Thérapie de combinaison avec des peptides époxycétones
AU2013100533B4 (en) *	2008-11-11	2013-12-12	Novartis Ag	Crystalline forms of fingolimod HCL
CA2743232C (fr) *	2008-11-11	2015-12-29	Novartis Ag	Formes cristallines de fingolimod hcl
US8680146B2 (en)	2008-11-11	2014-03-25	Novartis Ag	Organic compounds
RU2464271C1 (ru)	2008-12-17	2012-10-20	Дайити Санкио Компани, Лимитед	Способ получения производного диамина
WO2010082531A1 (fr)	2009-01-13	2010-07-22	第一三共株式会社	Inhibiteur d'un facteur actif de la coagulation sanguine
WO2010104078A1 (fr)	2009-03-10	2010-09-16	第一三共株式会社	Procédé de production d'un dérivé de diamine
EP2407450B1 (fr)	2009-03-13	2015-04-22	Daiichi Sankyo Company, Limited	Procédé de production d'un dérivé diamine optiquement actif
TWI504598B (zh)	2009-03-20	2015-10-21	Onyx Therapeutics Inc	結晶性三肽環氧酮蛋白酶抑制劑
TW201102064A (en) *	2009-06-18	2011-01-16	Daiichi Sankyo Co Ltd	Pharmaceutical composition having improved dissolution property
US9675566B2 (en)	2009-07-16	2017-06-13	Pathologica Llc	Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
EP2498793B1 (fr)	2009-11-13	2019-07-10	Onyx Therapeutics, Inc.	Oprozomib pour l'utilsation dans la suppression des metastases
US9359398B2 (en)	2010-03-01	2016-06-07	Onyx Therapeutics, Inc.	Compounds for immunoproteasome inhibition
JP5390014B2 (ja)	2010-03-19	2014-01-15	第一三共株式会社	抗凝固剤の溶出改善方法
JP5692873B2 (ja)	2010-03-19	2015-04-01	第一三共株式会社	ジアミン誘導体の結晶およびその製造方法
EA201291095A1 (ru) *	2010-04-22	2013-04-30	Рациофарм Гмбх	Способ получения пероральной лекарственной формы, содержащей финголимод
EP2589590B1 (fr)	2010-07-02	2016-12-28	Daiichi Sankyo Company, Limited	Procédé pour la préparation de sel dérivé de diamine optiquement actif
EP2646409A4 (fr)	2010-11-25	2015-12-16	Shilpa Medicare Ltd	Polymorphes du fingolimode et leurs procédés
SG191286A1 (en)	2011-01-07	2013-07-31	Novartis Ag	Immunosuppressant formulations
ES2662373T3 (es)	2011-01-19	2018-04-06	Pathologica, Llc.	Formas de dosificación farmacéutica oral de liberación controlada que comprenden MGBG
JO3177B1 (ar) *	2011-04-01	2018-03-08	Novartis Ag	تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
WO2013019872A1 (fr)	2011-08-01	2013-02-07	Teva Pharmaceutical Industries Ltd.	Procédé de préparation de compositions pharmaceutiques comprenant du fingolimod
JPWO2013022059A1 (ja)	2011-08-10	2015-03-05	第一三共株式会社	ジアミン誘導体含有医薬組成物
WO2013091704A1 (fr)	2011-12-22	2013-06-27	Synthon Bv	Composition pharmaceutique comprenant le fingolimod
RU2482842C1 (ru) *	2012-04-26	2013-05-27	Открытое акционерное общество "Новосибхимфарм"	Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) *	2012-06-13	2014-02-20	Открытое акционерное общество "Новосибхимфарм"	Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
WO2014011695A2 (fr)	2012-07-09	2014-01-16	Onyx Therapeutics, Inc.	Promédicaments d'inhibiteurs d'époxy cétone protéase peptidique
RU2496486C1 (ru) *	2012-07-11	2013-10-27	Александр Васильевич Иващенко	Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
CN105163730B (zh) *	2013-01-08	2018-10-30	帕萨罗杰卡有限公司	用于治疗脱髓鞘疾病的方法和组合物
WO2014141298A2 (fr) *	2013-03-11	2014-09-18	Astron Research Limited	Composition pharmaceutique stable de fingolimod
WO2014175287A1 (fr) *	2013-04-26	2014-10-30	国立大学法人京都大学	Composition médicinale destinée à empêcher la formation et/ou l'expansion d'un anévrisme cérébral ou réduire un tel anévrisme
MX370184B (es) *	2013-05-13	2019-12-04	Synthon Bv	Composición farmacéutica que comprende fingolimod.
JP6316422B2 (ja) *	2013-07-29	2018-04-25	アイザントドラッグリサーチソリューションズプライベートリミテッドＡｉｚａｎｔＤｒｕｇＲｅｓｅａｒｃｈＳｏｌｕｔｉｏｎｓＰｖｔＬｔｄ	フィンゴリモドの医薬組成物
RU2530626C1 (ru) *	2013-10-21	2014-10-10	Ооо "Валента-Интеллект"	Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
US20170231928A1 (en) *	2014-08-22	2017-08-17	Sunshine Lake Pharma Co., Ltd.	Solid composition of fingolimod and preparation thereof
WO2016042493A1 (fr) *	2014-09-19	2016-03-24	Aizant Drug Research Pvt. Ltd	Compositions pharmaceutiques de fingolimod
US9925138B2 (en)	2015-01-20	2018-03-27	Handa Pharmaceuticals, Llc	Stable solid fingolimod dosage forms
CA2974375A1 (fr) *	2015-01-20	2016-07-28	Handa Pharmaceuticals, Llc	Forme galenique solide stable de fingolimod
WO2016135644A1 (fr)	2015-02-26	2016-09-01	Novartis Ag	Traitement de maladie auto-immune chez un patient recevant en outre un bêtabloquant
RU2577230C1 (ru) *	2015-04-09	2016-03-10	Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус"	Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) *	2015-05-28	2017-06-27	Axogen Corporation	Quantitative structural assay of a nerve graft
US11434200B2 (en)	2017-03-09	2022-09-06	Novartis Ag	Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
WO2018178744A1 (fr)	2017-03-29	2018-10-04	Deva Holding Anonim Sirketi	Formulations stables de fingolimod
GR1009654B (el)	2018-08-31	2019-11-18	Φαρματεν Α.Β.Ε.Ε.	Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) *	2018-10-10	2020-04-16	Harbins Ruhr Bioscience, Inc.	Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
JP7503420B2 (ja) *	2020-05-18	2024-06-20	東和薬品株式会社	フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法
EP4181906A1 (fr)	2020-07-16	2023-05-24	Harbins Ruhr Bioscience, Inc.	Composés sphingoïdes à utiliser dans la prophylaxie et/ou la thérapie d'une infection par un coronavirus
EP4284348A2 (fr) *	2021-01-28	2023-12-06	Priothera SAS	Procédés de traitement avec des modulateurs du récepteur s1p
AU2021424131A1 (en) *	2021-01-28	2023-07-27	Priothera Limited	Methods of treatment with s1p receptor modulators

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL7607683A (nl) *	1976-07-12	1978-01-16	Akzo Nv	Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) *	1977-05-05	1978-08-29	Chevron Research Company	1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en)	1983-10-25	1985-12-17	Phillips Petroleum Company	Metal working lubricant
US5112616A (en)	1988-11-30	1992-05-12	Schering Corporation	Fast dissolving buccal tablet
JP2841857B2 (ja) *	1990-11-29	1998-12-24	田辺製薬株式会社	長期間安定な経口用医薬製剤
EP0627406B1 (fr)	1992-10-21	1998-10-28	Yoshitomi Pharmaceutical Industries, Ltd.	Compose 2-amino-1,3-propanediol et immunosuppresseur
ATE211726T1 (de)	1994-08-22	2002-01-15	Welfide Corp	Benzolderivate und deren medizinische verwendung
NZ324453A (en)	1995-12-28	2000-03-27	Yoshitomi Pharmaceutical	2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol for topical administration in order to inhibit rejection reactions at organ or bone marrow transplantation or treating autoimmune disease
JPH11209277A (ja) *	1998-01-19	1999-08-03	Yoshitomi Pharmaceut Ind Ltd	医薬組成物
US6476004B1 (en)	1996-07-18	2002-11-05	Mitsubishi Pharma Corporation	Pharmaceutical composition
JP2002241272A (ja)	1996-07-18	2002-08-28	Mitsubishi Pharma Corp	医薬処方組成物
GB9624038D0 (en)	1996-11-19	1997-01-08	Sandoz Ltd	Organic compounds
CN1178653C (zh) *	1997-02-27	2004-12-08	三菱制药株式会社	药物组合物
DE69830756T2 (de) *	1997-04-04	2006-05-04	Mitsubishi Pharma Corp.	2-Aminopropan-1,3-diol-Verbindungen, ihre medizinische Anwendung und Zwischenprodukte zu ihrer Synthese
JPH1180026A (ja)	1997-09-02	1999-03-23	Yoshitomi Pharmaceut Ind Ltd	新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja)	1998-04-01	2004-07-21	花王株式会社	スフィンゴ糖脂質の製造法
JP4627356B2 (ja) *	1999-06-30	2011-02-09	昭松森	ウイルス性心筋炎の予防または治療薬剤
WO2001003739A1 (fr) *	1999-07-12	2001-01-18	Ono Pharmaceutical Co., Ltd.	Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate
IL153594A0 (en)	2000-07-13	2003-07-06	Sankyo Co	Amino alcohol derivatives and pharmaceutical compositions containing the same
JP2004507552A (ja) *	2000-08-31	2004-03-11	メルク　エンド　カムパニー　インコーポレーテッド	免疫調節剤としてのリン酸誘導体
US6953332B1 (en)	2000-11-28	2005-10-11	St. Jude Medical, Inc.	Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
DE60208355T2 (de)	2001-03-26	2006-07-27	Novartis Ag	2-amino-propanol derivate
US7521192B2 (en)	2001-04-18	2009-04-21	Rigel Pharmaceuticals, Inc.	EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja)	2001-04-20	2002-10-31	Sankyo Co Ltd	ベンゾチオフェン誘導体
WO2003020313A1 (fr)	2001-09-04	2003-03-13	Ono Pharmaceutical Co., Ltd.	Medicaments contre les maladies respiratoires renfermant un agent de regulation du recepteur de la sphingosine-1-phosphate
DE60223699T2 (de)	2001-09-27	2008-10-30	Kyorin Pharmaceutical Co., Ltd.	Diarylsulfidderivat, dessen additionssalz und immunsuppressivum
DE60235900D1 (de)	2001-09-27	2010-05-20	Kyorin Seiyaku Kk	Osuppressivum
EP1513522A2 (fr)	2002-01-18	2005-03-16	Sri International	Procedes pour traiter des pathologies associees a un recepteur d'edg
EP1575964B1 (fr)	2002-01-18	2009-11-11	Merck & Co., Inc.	N-(benzyl)aminoalkyl carboxylates, phosphinates, phosphonates et tetrazoles en tant qu'agonistes de recepteur edg
WO2003061567A2 (fr)	2002-01-18	2003-07-31	Merck & Co., Inc.	Antagonistes sélectifs du récepteur s1p1/edg1
JP4430941B2 (ja)	2002-01-18	2010-03-10	メルクエンドカムパニーインコーポレーテッド	Ｅｄｇ受容体作動薬
PL1772145T3 (pl) *	2004-07-16	2011-08-31	Kyorin Seiyaku Kk	Sposób skutecznego stosowania leku i sposób dotyczący zapobiegania efektom ubocznym

2004
- 2004-04-06 US US10/552,005 patent/US20060275357A1/en not_active Abandoned
- 2004-04-06 HR HR20050886A patent/HRP20050886B1/xx not_active IP Right Cessation
- 2004-04-06 NZ NZ586280A patent/NZ586280A/en not_active IP Right Cessation
- 2004-04-06 PE PE2004000355A patent/PE20050396A1/es not_active Application Discontinuation
- 2004-04-06 AT ATA606/2004A patent/AT501681B1/de not_active IP Right Cessation
- 2004-04-06 AT AT04725895T patent/ATE414508T1/de active
- 2004-04-06 EP EP10186307A patent/EP2319502A1/fr not_active Withdrawn
- 2004-04-06 SG SG2008040545A patent/SG175449A1/en unknown
- 2004-04-06 DE DE102004016947A patent/DE102004016947A1/de not_active Ceased
- 2004-04-06 BR BRPI0409250A patent/BRPI0409250B8/pt active IP Right Grant
- 2004-04-06 GR GR20040100121A patent/GR1005052B/el unknown
- 2004-04-06 PE PE2013000382A patent/PE20131352A1/es active IP Right Grant
- 2004-04-06 MX MXPA05010860A patent/MXPA05010860A/es active IP Right Grant
- 2004-04-06 KR KR1020127019448A patent/KR101367574B1/ko not_active Expired - Lifetime
- 2004-04-06 DE DE201112100047 patent/DE122011100047I1/de active Pending
- 2004-04-06 CA CA2707750A patent/CA2707750A1/fr not_active Abandoned
- 2004-04-06 RU RU2005134173/15A patent/RU2358716C2/ru not_active IP Right Cessation
- 2004-04-06 DE DE602004017847T patent/DE602004017847D1/de not_active Expired - Lifetime
- 2004-04-06 ES ES200400852A patent/ES2228282B1/es not_active Expired - Fee Related
- 2004-04-06 ES ES10184951.1T patent/ES2556947T3/es not_active Expired - Lifetime
- 2004-04-06 PE PE2012002027A patent/PE20130200A1/es not_active Application Discontinuation
- 2004-04-06 HR HR20100600A patent/HRP20100600A2/hr not_active Application Discontinuation
- 2004-04-06 HR HRP20100601AA patent/HRP20100601B1/hr not_active IP Right Cessation
- 2004-04-06 DK DK04725895T patent/DK1613288T3/da active
- 2004-04-06 CN CN2004800092370A patent/CN1767819B/zh not_active Expired - Lifetime
- 2004-04-06 AU AU2004228929A patent/AU2004228929B2/en not_active Expired
- 2004-04-06 EP EP14163450.1A patent/EP2769713A1/fr not_active Withdrawn
- 2004-04-06 ES ES04725895T patent/ES2320767T3/es not_active Expired - Lifetime
- 2004-04-06 SI SI200431037T patent/SI1613288T1/sl unknown
- 2004-04-06 NZ NZ542622A patent/NZ542622A/xx not_active IP Right Cessation
- 2004-04-06 DE DE202004021680U patent/DE202004021680U1/de not_active Expired - Lifetime
- 2004-04-06 IT IT000682A patent/ITMI20040682A1/it unknown
- 2004-04-06 JP JP2004111761A patent/JP5495467B2/ja not_active Expired - Lifetime
- 2004-04-06 CN CN2010101213007A patent/CN101797241B/zh not_active Expired - Lifetime
- 2004-04-06 PE PE2015000303A patent/PE20150676A1/es not_active Application Discontinuation
- 2004-04-06 NZ NZ592339A patent/NZ592339A/xx not_active IP Right Cessation
- 2004-04-06 PL PL04725895T patent/PL1613288T3/pl unknown
- 2004-04-06 GB GB0407819A patent/GB2400318B/en not_active Expired - Lifetime
- 2004-04-06 PE PE2008001684A patent/PE20090743A1/es not_active Application Discontinuation
- 2004-04-06 CA CA2521325A patent/CA2521325C/fr not_active Expired - Lifetime
- 2004-04-06 WO PCT/EP2004/003656 patent/WO2004089341A1/fr not_active Ceased
- 2004-04-06 PT PT04725895T patent/PT1613288E/pt unknown
- 2004-04-06 KR KR1020057019066A patent/KR20050121712A/ko not_active Ceased
- 2004-04-06 FR FR0450692A patent/FR2854073B1/fr not_active Expired - Lifetime
- 2004-04-06 DK DK10184951.1T patent/DK2316431T3/en active
- 2004-04-06 PL PL10184951.1T patent/PL2316431T3/pl unknown
- 2004-04-06 KR KR1020107029859A patent/KR20110005320A/ko not_active Ceased
- 2004-04-06 AR ARP040101162A patent/AR043987A1/es not_active Application Discontinuation
- 2004-04-06 EP EP10184951.1A patent/EP2316431B1/fr not_active Revoked
- 2004-04-06 SI SI200432283T patent/SI2316431T1/sl unknown
- 2004-04-06 EP EP04725895A patent/EP1613288B1/fr not_active Expired - Lifetime
- 2004-04-06 HU HUE10184951A patent/HUE028247T2/en unknown
- 2004-04-06 EP EP08161161A patent/EP2008650A3/fr not_active Withdrawn
- 2004-04-07 BE BE2004/0180A patent/BE1015972A5/fr not_active IP Right Cessation
- 2004-04-07 TW TW093109631A patent/TWI332847B/zh active
- 2004-04-07 MY MYPI20041275A patent/MY141249A/en unknown
- 2004-04-07 CL CL200400745A patent/CL2004000745A1/es unknown
2005
- 2005-09-14 ZA ZA200507394A patent/ZA200507394B/en unknown
- 2005-09-15 IL IL170888A patent/IL170888A/en active IP Right Grant
- 2005-10-07 EC EC2005006090A patent/ECSP056090A/es unknown
- 2005-10-07 TN TNP2005000256A patent/TNSN05256A1/en unknown
- 2005-10-19 MA MA28560A patent/MA27729A1/fr unknown
- 2005-11-01 IS IS8114A patent/IS2682B/is unknown
- 2005-11-07 NO NO20055231A patent/NO329332B1/no active Protection Beyond IP Right Term
2008
- 2008-05-08 AT AT0074408A patent/AT504853A2/de not_active Application Discontinuation
- 2008-08-11 US US12/189,323 patent/US8324283B2/en not_active Expired - Fee Related
- 2008-08-13 US US12/191,098 patent/US20090203798A1/en not_active Abandoned
2009
- 2009-02-17 RU RU2009105403/15A patent/RU2009105403A/ru not_active Application Discontinuation
- 2009-02-19 CY CY20091100192T patent/CY1110260T1/el unknown
- 2009-03-12 IL IL197578A patent/IL197578A/en active IP Right Grant
2010
- 2010-02-18 NO NO20100250A patent/NO334116B1/no unknown
- 2010-02-25 IS IS8885A patent/IS8885A/is unknown
- 2010-08-25 JP JP2010188835A patent/JP5543298B2/ja not_active Expired - Lifetime
- 2010-10-26 AR ARP100103930A patent/AR078781A2/es not_active Application Discontinuation
- 2010-10-26 AR ARP100103931A patent/AR078782A2/es not_active Application Discontinuation
- 2010-11-17 RU RU2010146697/15A patent/RU2475236C2/ru active
- 2010-11-18 RU RU2010147000/15A patent/RU2475237C2/ru active
2011
- 2011-01-10 US US12/987,726 patent/US20110105620A1/en not_active Abandoned
- 2011-03-01 CL CL2011000450A patent/CL2011000450A1/es unknown
- 2011-09-06 HU HUS1100016C patent/HUS1100016I1/hu unknown
- 2011-09-08 LU LU91867C patent/LU91867I2/fr unknown
- 2011-09-08 BE BE2011C030C patent/BE2011C030I2/fr unknown
- 2011-09-08 NO NO2011016C patent/NO2011016I2/no unknown
- 2011-09-08 CY CY2011013C patent/CY2011013I2/el unknown
- 2011-09-08 FR FR11C0036C patent/FR11C0036I2/fr active Active
2012
- 2012-11-15 RU RU2012148593/15A patent/RU2012148593A/ru not_active Application Discontinuation
- 2012-12-20 US US13/721,278 patent/US20130108675A1/en not_active Abandoned
2013
- 2013-04-23 JP JP2013090602A patent/JP2013177404A/ja active Pending
- 2013-09-16 US US14/027,943 patent/US20140011885A1/en not_active Abandoned
- 2013-09-26 NO NO20131287A patent/NO335120B1/no unknown
2014
- 2014-05-23 US US14/285,808 patent/US20140255497A1/en not_active Abandoned
2015
- 2015-10-12 IL IL242037A patent/IL242037A0/en unknown
- 2015-12-29 CY CY20151101194T patent/CY1117071T1/el unknown
2017
- 2017-06-27 US US15/634,579 patent/US20170290787A1/en not_active Abandoned
2019
- 2019-02-13 US US16/274,357 patent/US20190175527A1/en not_active Abandoned
2020
- 2020-04-03 US US16/839,703 patent/US20200237690A1/en not_active Abandoned
2021
- 2021-10-14 US US17/501,173 patent/US20220031609A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20200237690A1 (en)	2020-07-30
MXPA05010860A (es)	2006-05-25
ES2228282A1 (es)	2005-04-01
WO2004089341A1 (fr)	2004-10-21
CN101797241B (zh)	2013-03-27
IS8114A (is)	2005-11-01
CN101797241A (zh)	2010-08-11
HK1155647A1 (en)	2012-05-25
US20140011885A1 (en)	2014-01-09
US20170290787A1 (en)	2017-10-12
SI2316431T1 (sl)	2016-04-29
PE20050396A1 (es)	2005-07-05
TW200503784A (en)	2005-02-01
DE122011100047I1 (de)	2011-12-15
HUE028247T2 (en)	2016-12-28
HUS1100016I1 (hu)	2016-08-29
SI1613288T1 (sl)	2009-04-30
TWI332847B (en)	2010-11-11
AT501681B1 (de)	2012-04-15
DK2316431T3 (en)	2016-01-11
IL170888A (en)	2010-06-16
CY1110260T1 (el)	2014-04-09
CY2011013I1 (el)	2014-04-09
JP5543298B2 (ja)	2014-07-09
DE602004017847D1 (de)	2009-01-02
CL2004000745A1 (es)	2005-02-11
NZ592339A (en)	2012-09-28
HRP20100601A2 (hr)	2011-03-31
LU91867I2 (fr)	2011-11-08
RU2358716C2 (ru)	2009-06-20
JP2013177404A (ja)	2013-09-09
CA2521325C (fr)	2010-09-14
US20140255497A1 (en)	2014-09-11
ITMI20040682A1 (it)	2004-07-06
JP5495467B2 (ja)	2014-05-21
GR20040100121A (el)	2004-12-17
GB2400318A (en)	2004-10-13
AR078782A2 (es)	2011-11-30
MY141249A (en)	2010-03-31
US20190175527A1 (en)	2019-06-13
IS2682B (is)	2010-10-15
RU2005134173A (ru)	2006-09-10
NO20131287L (no)	2006-01-09
EP2316431B1 (fr)	2015-09-30
GR1005052B (el)	2005-11-30
CY2011013I2 (el)	2014-04-09
NO2011016I1 (no)	2011-09-19
PE20150676A1 (es)	2015-05-17
NO20055231L (no)	2006-01-09
PL2316431T3 (pl)	2016-09-30
RU2010146697A (ru)	2012-05-27
NZ586280A (en)	2011-12-22
ZA200507394B (en)	2007-03-28
BE2011C030I2 (fr)	2023-03-07
AU2004228929B2 (en)	2008-02-07
US20090203798A1 (en)	2009-08-13
NZ542622A (en)	2009-01-31
BRPI0409250B8 (pt)	2022-01-18
US20060275357A1 (en)	2006-12-07
SG175449A1 (en)	2011-11-28
US20080311188A1 (en)	2008-12-18
PE20130200A1 (es)	2013-03-09
LU91867I9 (fr)	2019-01-03
PT1613288E (pt)	2009-02-25
US20130108675A1 (en)	2013-05-02
BRPI0409250B1 (pt)	2017-07-11
ES2320767T3 (es)	2009-05-28
RU2010147000A (ru)	2012-08-10
HK1091114A1 (en)	2007-01-12
EP1613288B1 (fr)	2008-11-19
IS8885A (is)	2010-02-25
IL242037A0 (en)	2015-11-30
HRP20050886A2 (en)	2006-11-30
NO335120B1 (no)	2014-09-22
EP2319502A1 (fr)	2011-05-11
FR2854073A1 (fr)	2004-10-29
EP1613288A1 (fr)	2006-01-11
IE20040246A1 (en)	2004-12-15
RU2475236C2 (ru)	2013-02-20
DK1613288T3 (da)	2009-03-23
BRPI0409250A (pt)	2006-03-28
FR11C0036I1 (fr)	2011-10-14
EP2008650A2 (fr)	2008-12-31
BE1015972A5 (fr)	2005-12-06
CL2011000450A1 (es)	2011-11-25
PE20131352A1 (es)	2013-11-14
AR043987A1 (es)	2005-08-17
ECSP056090A (es)	2006-03-01
PE20090743A1 (es)	2009-07-17
NO20100250L (no)	2006-01-09
US20110105620A1 (en)	2011-05-05
IL197578A0 (en)	2011-07-31
KR101367574B1 (ko)	2014-02-25
ATE414508T1 (de)	2008-12-15
MA27729A1 (fr)	2006-01-02
RU2009105403A (ru)	2010-08-27
CA2707750A1 (fr)	2004-10-21
AU2004228929A1 (en)	2004-10-21
EP2769713A1 (fr)	2014-08-27
RU2475237C2 (ru)	2013-02-20
CY1117071T1 (el)	2017-04-05
CN1767819B (zh)	2010-07-28
NO2011016I2 (no)	2012-08-27
AT504853A2 (de)	2008-08-15
US20220031609A1 (en)	2022-02-03
HRP20100601B1 (hr)	2016-12-02
NO329332B1 (no)	2010-09-27
JP2004307506A (ja)	2004-11-04
FR11C0036I2 (fr)	2023-12-29
AR078781A2 (es)	2011-11-30
AT501681A1 (de)	2006-10-15
ES2228282B1 (es)	2006-02-16
CN1767819A (zh)	2006-05-03
GB2400318B (en)	2005-08-10
DE202004021680U1 (de)	2010-04-22
CA2521325A1 (fr)	2004-10-21
US8324283B2 (en)	2012-12-04
HRP20050886B1 (en)	2011-01-31
RU2012148593A (ru)	2014-05-20
GB0407819D0 (en)	2004-05-12
PL1613288T3 (pl)	2009-07-31
ES2556947T3 (es)	2016-01-21
KR20110005320A (ko)	2011-01-17
IL197578A (en)	2015-10-29
TNSN05256A1 (en)	2007-07-10
NO334116B1 (no)	2013-12-16
NO20055231D0 (no)	2005-11-07
KR20050121712A (ko)	2005-12-27
HRP20100600A2 (hr)	2011-03-31
EP2008650A3 (fr)	2011-04-27
KR20120101148A (ko)	2012-09-12
JP2011006461A (ja)	2011-01-13
EP2316431A1 (fr)	2011-05-04
HK1071685A1 (en)	2005-07-29
DE102004016947A1 (de)	2004-10-21

Publication	Publication Date	Title
FR2854073B1 (fr)	2008-03-14	Composition pharmaceutique solide comprenant un agoniste du recepteur s1p et un alcool de sucre
DK1185253T3 (da)	2004-04-05	Oralt præparat til indgivelse af en fast kombination af tramadol og diclofenac
NO20081218L (no)	2008-04-29	Flytende formuleringer
ATE380023T1 (de)	2007-12-15	Orale feste pharmazeutische zusammensetzungen zur ph-abhängig mehrphasigen freisetzung
FR2850576B1 (fr)	2007-03-23	Composition comprenant un melange de principes actifs, et procede de preparation
ECSP045493A (es)	2005-03-10	Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
EP1648697A4 (fr)	2011-12-21	Procede d'augmentation de la capacite d'un dispositif d'analyse clinique automatique au moyen d'elements d'administration de reactif modulaires
CO5580741A2 (es)	2005-11-30	Composicion farmaceutica que comprende un agonista de receptor de 5ht1
FR2867682B1 (fr)	2009-06-05	Composition pharmaceutique anhydre associant un agent silicone et un principe actif solubilise.
WO2008060546A3 (fr)	2009-04-30	Formulations orales
NO20064808L (no)	2006-12-15	Orale matrixformuleringer med licarbazepin
EA200601015A1 (ru)	2006-10-27	Пероральные композиции дезоксипеганина и их применение
NO20064783L (no)	2006-12-15	Opplosningstabeletter med licarbazepin
TH87290A (th)	2007-10-31	สารองค์ประกอบทางเภสัชกรรมชนิดใหม่ที่ประกอบด้วยเลเวไทราซีแทม และกระบวนการสำหรับการเตรียมสารนั้น

Legal Events

Date	Code	Title	Description
2013-08-09	CA	Change of address	Effective date: 20130703
2013-08-09	CD	Change of name or company name	Owner name: MITSUBISHI TANABE PHARMA CORPORATION, JP Effective date: 20130703 Owner name: NOVARTIS AG, CH Effective date: 20130703
2013-08-09	TQ	Partial transmission of property	Owner name: MITSUBISHI TANABE PHARMA CORPORATION, JP Effective date: 20130703 Owner name: NOVARTIS AG, CH Effective date: 20130703
2016-03-09	PLFP	Fee payment	Year of fee payment: 13
2017-03-27	PLFP	Fee payment	Year of fee payment: 14
2018-03-27	PLFP	Fee payment	Year of fee payment: 15
2020-03-26	PLFP	Fee payment	Year of fee payment: 17
2021-03-25	PLFP	Fee payment	Year of fee payment: 18
2022-03-21	PLFP	Fee payment	Year of fee payment: 19
2023-04-11	PLFP	Fee payment	Year of fee payment: 20